Overview

• Biotechnology company's Q1 revenue dropped sharply due to lower license payments and royalty declines

• Company posted a Q1 net loss, reversing a profit in the prior-year period

Outlook

• Company expects cash balance to fund operations into early 2027

Result Drivers

• REVENUE DECLINE - Co attributed lower Q1 revenue to absence of prior-year $70 mln upfront license payment and $12.2 mln drop in Zolgensma royalty revenue after patent expiration

• HIGHER R&D COSTS - Increased clinical trial expenses for RGX-202 and personnel-related costs drove up research and development expenses

Company press release: ID:nPn1rTLjMa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$1.72
Q1 Net Income		-$90.05 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Regenxbio Inc is $27.00, about 168.9% above its May 13 closing price of $10.04

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.